Literature DB >> 15895080

Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.

Zhe Li1, Frank J Godinho, Jan-Henning Klusmann, Mireia Garriga-Canut, Channing Yu, Stuart H Orkin.   

Abstract

Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient leukemia) and the related acute megakaryoblastic leukemia (DS-AMKL, also called DS-AML M7). These mutations lead to production of a variant GATA1 protein (GATA1s) that is truncated at its N terminus. To understand the biological properties of GATA1s and its relation to DS-AMKL and TMD, we used gene targeting to generate Gata1 alleles that express GATA1s in mice. We show that the dominant action of GATA1s leads to hyperproliferation of a unique, previously unrecognized yolk sac and fetal liver progenitor, which we propose accounts for the transient nature of TMD and the restriction of DS-AMKL to infants. Our observations raise the possibility that the target cells in other leukemias of infancy and early childhood are distinct from those in adult leukemias and underscore the interplay between specific oncoproteins and potential target cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895080     DOI: 10.1038/ng1566

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  116 in total

Review 1.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

3.  The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor.

Authors:  Barbara Ghinassi; Massimo Sanchez; Fabrizio Martelli; Giovanni Amabile; Alessandro Maria Vannucchi; Giovanni Migliaccio; Stuart H Orkin; Anna Rita Migliaccio
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

4.  Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Authors:  Ming-Horng Tsai; Jia-Woei Hou; Chao-Ping Yang; Pong-Hong Yang; Shih-Ming Chu; Jen-Fu Hsu; Ming-Chou Chiang; Hsuan-Rong Huang
Journal:  Indian J Pediatr       Date:  2011-02-02       Impact factor: 1.967

5.  Dominant-interfering C/EBPalpha stimulates primitive erythropoiesis in zebrafish.

Authors:  Ting Xi Liu; Jennifer Rhodes; Min Deng; Karl Hsu; Hanna S Radomska; John P Kanki; Daniel G Tenen; A Thomas Look
Journal:  Exp Hematol       Date:  2007-02       Impact factor: 3.084

Review 6.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

7.  Novel role for EKLF in megakaryocyte lineage commitment.

Authors:  Pilar Frontelo; Deepa Manwani; Mariann Galdass; Holger Karsunky; Felix Lohmann; Patrick G Gallagher; James J Bieker
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

8.  Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.

Authors:  Ying Xie; Mia Lee Koch; Xin Zhang; Melanie J Hamblen; Frank J Godinho; Yuko Fujiwara; Huafeng Xie; Jan-Henning Klusmann; Stuart H Orkin; Zhe Li
Journal:  Stem Cells       Date:  2017-04-24       Impact factor: 6.277

Review 9.  Constitutional aneuploidy and cancer predisposition.

Authors:  Ithamar Ganmore; Gil Smooha; Shai Izraeli
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

10.  Trisomy 21 enhances human fetal erythro-megakaryocytic development.

Authors:  Stella T Chou; Joanna B Opalinska; Yu Yao; Myriam A Fernandes; Anna Kalota; John S J Brooks; John K Choi; Alan M Gewirtz; Gwenn-ael Danet-Desnoyers; Richard L Nemiroff; Mitchell J Weiss
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.